ALT Deadline: ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. by shareholders, alleging that the company misled investors regarding its business operations and the potential of its lead product candidate, pemvidutide [1][2]. Group 1: Allegations and Misleading Statements - The lawsuit claims that Altimmune overstated the potential of pemvidutide compared to competing GLP-1 agonists based on efficacy and tolerability results from the MOMENTUM Trial [2]. - It is alleged that the results of the MOMENTUM trial were less significant for pemvidutide's clinical and commercial prospects than what was communicated to investors [2]. - The lawsuit asserts that Altimmune's public statements were materially false and misleading, leading to investor damages when the true details emerged [2]. Group 2: Legal Proceedings and Participation - Shareholders wishing to serve as lead plaintiffs must file motions by July 5, 2024, and can participate in the class action without being actively involved in the case [1][3]. - The representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [3].